Management of Warfarin in Mitral Stenosis with INR 4.4 and No Bleeding
For this patient with rheumatic mitral stenosis on warfarin with an INR of 4.4 and no bleeding, you should withhold warfarin for 1-2 doses and monitor serial INR determinations without administering vitamin K, then resume warfarin at a reduced weekly dose once the INR returns to the therapeutic range of 2.0-3.0. 1
Immediate Management
Hold warfarin temporarily for 1-2 doses until the INR falls back into the therapeutic range (2.0-3.0), which typically occurs within 24-72 hours in most patients. 1
Do not administer vitamin K at this INR level unless the patient has high-risk bleeding factors such as advanced age (>65-75 years), history of prior bleeding, concurrent antiplatelet therapy, renal insufficiency, anemia, or alcohol use. 1 Since your patient has no bleeding tendencies and the INR is only 4.4, vitamin K is not indicated. 1
Why Vitamin K Is Not Needed
The evidence is clear: even when the INR is between 4.5-10.0, the absolute daily risk of major bleeding remains low, leading most physicians to manage these patients expectantly by simply stopping warfarin. 1 The American College of Chest Physicians pooled four randomized controlled trials showing no reduction in major bleeding rates (2% with vitamin K versus 0.8% with placebo) despite faster INR normalization. 2 Clinically significant bleeding risk does not rise appreciably until the INR exceeds 5.0, after which it increases exponentially. 1, 2
Critical Consideration for Mitral Stenosis
Warfarin remains the only recommended anticoagulant for patients with moderate-to-severe mitral stenosis. 1 Direct oral anticoagulants (DOACs) are explicitly contraindicated in this population. 1 The therapeutic INR target for rheumatic mitral valve disease is 2.5 (range 2.0-3.0), whether or not atrial fibrillation is present. 1, 3
Monitoring Schedule
- Recheck INR within 24-48 hours after withholding warfarin to confirm the value is declining appropriately. 1
- Continue monitoring every 24-48 hours until the INR returns to the therapeutic range of 2.0-3.0. 1
- Once stable in the therapeutic range for 2-3 consecutive days, reduce monitoring frequency to 2-3 times weekly for 1-2 weeks, then weekly for 1 month, and finally monthly once stability is confirmed. 1
Resuming Warfarin Therapy
Restart warfarin at a reduced weekly dose (decrease by 10-20%) when the INR approaches the therapeutic range to prevent recurrence of supratherapeutic INR. 1, 2, 4 For example, if the patient was taking 35 mg per week (5 mg daily), reduce to approximately 28-31.5 mg per week (4-4.5 mg daily). 1, 2
Investigate the Cause
Before resuming warfarin, systematically evaluate potential contributors to the INR elevation:
- Medication changes (especially antibiotics, which are the most common cause of unexpected INR elevation). 1, 2
- Dietary changes affecting vitamin K intake (reduced consumption of green vegetables or use of vitamin K supplements). 1, 2
- Intercurrent illness (fever, diarrhea, reduced oral intake, dehydration). 1, 2
- Changes in hepatic or renal function. 1, 2
- Medication adherence issues. 1
Common Pitfalls to Avoid
Do not give vitamin K reflexively for an INR of 4.4 without bleeding, as this can induce warfarin resistance lasting up to one week and make re-anticoagulation extremely difficult. 1, 2 High-dose vitamin K (≥10 mg) is particularly problematic and should never be used in non-bleeding scenarios. 1, 2
Do not consider switching to a DOAC in this patient with mitral stenosis, as NOACs are contraindicated in moderate-to-severe mitral stenosis. 1 The 2019 AHA/ACC/HRS guidelines explicitly state that NOACs should only be used in AF patients "except with moderate-to-severe mitral stenosis or a mechanical heart valve." 1
Do not delay addressing the underlying cause of the INR elevation, as failure to identify and correct precipitating factors will lead to recurrent supratherapeutic INR values. 1, 2